Department of Research and Technology, Isfahan University of Medical Sciences, Isfahan, Iran
Review Article
A Quick Review of SGLT2 Inhibitor Empagliflozin in Clinical Practice
Author(s): Zahra Tolou Ghamari*
Empagliflozin or Jardiance could be prescribed in forms of immunotherapy or polypharmacy with metformin or insulin for patients with diabetes as an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, Sodium Glucose Contransporter Type 2 (SGLT2) inhibitor and albuminuria lowering agent. The aim of this review was to provide updated information associated with the clinical pharmacokinetics and pharmacotherapy of empagliflozin. This review was conducted according to published PRISMA guidelines. SGLT2 plays a crucial role in glucose transport and intraadrenal osmolality. In fact SGLT2 actively mediated 90% reabsorption of glucose by the kidneys. The over activation of SGLT2 in diabetic patients, leads to an increase in glucose and sodium reabsorption. Empagliflozin inhibits this contransporter that leads to loss of glucose in the urine and a reduction in hyp.. View More»
DOI:
DOI: 10.35248/JPR.22.6.127